Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063944 | 1.00 | MAPT (0.47) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL3063942 | 0.81 | MAPT (0.59) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL14291439 | 0.81 | MAPT (0.59) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL14291437 | 0.72 | MAPT (0.58) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL13091221 | 0.69 | MAPT (0.60) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL13942702 | 0.68 | MAPT (0.54) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL11059702 | 0.68 | LMNA (0.75) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL11810697 | 0.67 | LMNA (1.00) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL29345146 | 0.67 | LMNA (0.94) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL14128251 | 0.65 | LMNA (0.83) | MAPTLMNAHTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194783-B1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-8618110-B2 | Compositions and methods for apoptosis modulators | VM DISCOVERY INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2008021250-A2 | COMPOSITIONS AND METHODS FOR MODULATING APOPTOSIS IN CELLS OVER-EXPRESSING BCL-2 FAMILY MEMBER PROTEINS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | BAX, BCL2, BAD | MAPT 2663/4885LMNA 125/4885HTT 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.